pH-sensitive multi-drug liposomes targeting folate receptor β for efficient treatment of non-small cell lung cancer

J Control Release. 2021 Feb 10:330:1-14. doi: 10.1016/j.jconrel.2020.12.011. Epub 2020 Dec 13.

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of lung cancer-related deaths worldwide. Tumor-associated macrophages (TAMs), which can be polarized into tumor-promoting M2 phenotype, overexpress folate receptor beta (FRβ) and are associated with poor prognosis in NSCLC. In addition, calpain-2 (CAPN2) is overexpressed in NSCLC and is involved in tumor growth. To improve the anticancer efficacy of drugs and reduce their side effects in the treatment of NSCLC, it is important to develop smart drug delivery systems with specific targeting ability and controlled release mechanisms. In this study, FRβ-targeted pH-sensitive liposomes were designed as carriers to ensure efficient drug delivery and acid-responsive release in NSCLC cells. Folate-mediated targeting of FRβ in M2 TAMs and NSCLC cells effectively inhibited tumor growth and the stimulus-responsive drug release reduced the toxic side effects of the drug. The combination of doxycycline (anti-CAPN2) and docetaxel (anticancer drug) showed a synergistic inhibitory effect on tumor growth by suppressing CAPN2 expression.

Keywords: Calpain-2; Folate receptor beta; Non-small cell lung cancer; Tumor microenvironment; pH-sensitive.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Cell Line, Tumor
  • Folate Receptor 2*
  • Humans
  • Hydrogen-Ion Concentration
  • Liposomes
  • Lung Neoplasms* / drug therapy

Substances

  • Folate Receptor 2
  • Liposomes